Lonza

This morning, we announced that we have signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion subject to regulatory approvals. 

The Vacaville (US) facility is one of the largest biologics manufacturing sites in the world by volume. After closing, this highly valuable and strategic acquisition provides an immediate and significant capacity increase to meet demand for commercial manufacturing services from our mammalian customers. The acquisition also supports the continuing growth of our Biologics division.

Read more: https://lnkd.in/didj56ZP

#AHealthierWorld #Vacaville #Biologics

We are excited to let you know about our new Drug Product Services’ non-GMP manufacturing line at Stuecki Park Basel. Equipped with leading-edge automated systems, it is already successfully filling batches. Want to learn more? Contact our experts. 

https://lnkd.in/emtRYEEp

#Lonza, #LonzaDPS, #steriledrugproduct, #parenteraldrugproduct, #drugproduct, #PatientCareFirst